25 studies found for:    "gene therapy" OR "gene transfer" OR "virus delivery" | plasmid
Show Display Options
Rank Status Study
1 Completed Gene Therapy of Pancreatic Ductal Adenocarcinoma
Condition: Gene Therapy in Pancreatic Adenocarcinoma
Intervention: Genetic: Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes
2 Completed Angiogenesis Using VEGF-A165/bFGF Plasmid Delivered Percutaneously in No-option CAD Patients; a Controlled Trial
Condition: Coronary Artery Disease
Intervention: Genetic: intramyocardial injection of VEGF-A165/bFGF:placebo plasmid
3 Completed The Effect of Mobilized Stem Cell by G-CSF and VEGF Gene Therapy in Patients With Stable Severe Angina Pectoris
Condition: Ischemic Heart Disease
Intervention: Genetic: VEGF-A165 plasmid
4 Recruiting Safety and Efficacy of Subjects With Critical Limb Ischemia
Condition: Critical Limb Ischemia
Intervention: Genetic: HGF Plasmid (AMG0001)
5 Not yet recruiting Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Peripheral Nerve Injury
Condition: Peripheral Nerve Injury
Intervention: Drug: Neovasculgen
6 Completed Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
Condition: Critical Limb Ischemia
Interventions: Genetic: Low Dose VM202;   Genetic: High Dose VM202;   Other: Placebo
7 Recruiting A Phase IIB Pilot Study of a Modified Dosage Regimen of AMG0001 in Subjects With Critical Limb Ischemia
Conditions: Critical Limb Ischemia;   Vascular Diseases;   Peripheral Arterial Disease
Intervention: Genetic: HGF Plasmid
8 Active, not recruiting Interleukin-12 Gene and in Vivo Electroporation-Mediated Plasmid DNA Vaccine Therapy in Treating Patients With Merkel Cell Cancer
Conditions: Recurrent Neuroendocrine Carcinoma of the Skin;   Stage I Neuroendocrine Carcinoma of the Skin;   Stage II Neuroendocrine Carcinoma of the Skin;   Stage III Neuroendocrine Carcinoma of the Skin;   Stage IV Neuroendocrine Carcinoma of the Skin
Interventions: Biological: interleukin-12 gene;   Biological: electroporation-mediated plasmid DNA vaccine therapy;   Other: laboratory biomarker analysis
9 Terminated Gene Electrotransfer to Muscle With Plasmid AMEP in Patients With Disseminated Cancer
Condition: Metastatic Malignant Neoplasm
Intervention: Drug: Plasmid AMEP
10 Not yet recruiting Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's Phenomenon
Condition: Secondary Raynaud's Phenomenon
Intervention: Drug: Neovasculgen
11 Completed Safety and Efficacy Study Using Gene Therapy for Critical Limb Ischemia
Conditions: Arterial Occlusive Disease;   Ulcers;   Ischemia;   Peripheral Vascular Disease
Interventions: Genetic: NL003;   Other: Normal Saline
12 Completed Trial of VLTS-589 in Subjects With Intermittent Claudication
Conditions: Intermittent Claudication;   Peripheral Vascular Disease
Intervention: Genetic: Plasmid based Gene Transfer product-VLTS-589
13 Completed EW-A-401 to Treat Intermittent Claudication
Conditions: Intermittent Claudication;   Arteriosclerosis
Interventions: Drug: DNA Plasmid Vector;   Drug: EW-A-401 DNA Plasmid Vector
14 Recruiting Trial of pIL-12 Electroporation Malignant Melanoma
Condition: Melanoma
Interventions: Biological: Plasmid INTERLEUKIN-12;   Device: Intratumoral Electroporation
15 Not yet recruiting Trial of pIL-12 Electroporation in Squamous Cell Carcinoma of the Head and Neck (IL12HNSCC)
Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Biological: Plasmid interleukin-12;   Device: Intratumoral electroporation
16 Recruiting Study of a DNA Immunotherapy to Treat Melanoma
Condition: Malignant Melanoma
Intervention: Biological: SCIB1
17 Enrolling by invitation Gene-activated Matrix for Bone Tissue Repair in Maxillofacial Surgery
Conditions: Maxillofacial Bone Defects;   Alveolar Bone Atrophy;   Jaw Fractures;   Maxillofacial Bone Deformities;   Bone Neoplasm, Benign;   Disorders of Teeth and Jaw
Intervention: Device: Gene-activated matrix "Nucleostim"
18 Completed Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer
Condition: Head and Neck Cancer
Interventions: Biological: gene therapy;   Biological: interleukin-2 gene;   Drug: methotrexate
19 Completed Phase I Trial of Intratumoral pIL-12 Electroporation in Malignant Melanoma
Condition: Malignant Melanoma
Interventions: Genetic: IL-12pDNA;   Procedure: electroporation
20 Completed A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing
Conditions: Breast Cancer;   Ovarian Cancer;   Prostate Cancer;   Colon Cancer;   Renal Cancer
Intervention: Drug: Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
Indicates status has not been verified in more than two years